Lynparza’s label includes detail about ... and that is a huge accomplishment,” Munster concludes. "Ovarian cancer: four drug ...

The CDF covers the cost of cancer drugs until confirmatory ... treatment of women with BRCA-positive ovarian cancer. The new recommendation will help Lynparza stay ahead of its rivals in the ...

Olaparib or Lynparza is approved for targeting advanced ovarian cancer with a gene mutation, as a first-line treatment Drugs advisory body NICE, the National Institute for Health and Care ...

Lynparza is approved for four cancer types — ovarian, breast ... Keytruda is the biggest product in Merck’s portfolio. The drug has played an instrumental role in driving Merck’s steady ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer ...

The defendants are looking to manufacture a generic version of AstraZeneca's cancer medication. The drug at the center of the suits, Lynparza, is an oral medication used to treat ovarian ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

To Know in detail about the Ovarian Cancer market outlook, drug uptake, treatment scenario ... RUBRACA (Rucaparib), ZEJULA (Niraparib), and LYNPARZA (Olaparib). . In January 2025, the FDA ...